2023
The role of volume of disease for treatment selection in patients with metastatic castration sensitive prostate cancer (mCSPC): A living meta-analysis.
Naqvi S, Riaz I, He H, Imran M, Orme J, Childs D, Ravi P, Hussain S, Singh P, Bryce A. The role of volume of disease for treatment selection in patients with metastatic castration sensitive prostate cancer (mCSPC): A living meta-analysis. Journal Of Clinical Oncology 2023, 41: 5088-5088. DOI: 10.1200/jco.2023.41.16_suppl.5088.Peer-Reviewed Original ResearchMetastatic castration-sensitive prostate cancerVolume of diseaseTriplet therapyDoublet therapyLV diseaseHazard ratioCastration-sensitive prostate cancerSensitive prostate cancerLow-volume diseaseEfficacious treatment optionConfidence intervalsInverse variance approachMixed treatment comparisonMCSPC patientsTreatment intensificationTreatment optionsClinical trialsProstate cancerEfficacious treatmentTreatment selectionDisease subgroupsPatientsComparative effectivenessTherapyDiseaseFirst-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer
Bin Riaz I, Naqvi S, He H, Asghar N, Siddiqi R, Liu H, Singh P, Childs D, Ravi P, Hussain S, Murad M, Boorjian S, Sweeney C, Van Allen E, Bryce A. First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer. JAMA Oncology 2023, 9: 635-645. PMID: 36862387, PMCID: PMC9982744, DOI: 10.1001/jamaoncol.2022.7762.Peer-Reviewed Original ResearchConceptsMetastatic castration-sensitive prostate cancerCastration-sensitive prostate cancerAndrogen pathway inhibitorsSystemic treatment optionsProgression-free survivalOverall survivalTreatment optionsClinical trialsTriplet therapyProstate cancerFirst-line systemic treatment optionComparative effectivenessFirst-line treatment optionHigh-volume diseaseHigher adverse eventsImproved overall survivalLow-volume diseaseHealth-related qualityFuture clinical trialsDifferent treatment optionsHeterogeneous patient populationVolume of diseaseOutcomes of interestTriplet regimensEligible RCTsAdjuvant immunotherapy in renal cell carcinoma: A living systematic review and network meta-analysis (NMA).
Sipra Q, Bin Riaz I, Naqvi S, He H, Siddiqi R, Islam M, Asghar N, Ikram W, Xu W, Singh P, Ho T, Bilen M, Zakharia Y, Bryce A. Adjuvant immunotherapy in renal cell carcinoma: A living systematic review and network meta-analysis (NMA). Journal Of Clinical Oncology 2023, 41: 694-694. DOI: 10.1200/jco.2023.41.6_suppl.694.Peer-Reviewed Original ResearchRenal cell carcinomaDisease-free survivalAdjuvant immunotherapyBaseline riskCell carcinomaTreatment optionsImproved disease-free survivalLocalized Renal Cell CarcinomaRisk categoriesAdjuvant treatment optionsAbsolute risk differenceUnique treatment optionRisk stratification systemMixed treatment comparisonSignificant differencesRelative effect estimatesEvidence synthesis frameworkAdjuvant pembrolizumabNivolumab-ipilimumabOverall survivalTreatment landscapeAbsolute benefitPreferred treatmentRecent trialsDisease progression
2022
Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis
Riaz I, Sipra Q, Naqvi S, He H, Siddiqi R, Islam M, Asghar N, Ikram W, Xu W, Liu H, Singh P, Ho T, Bilen M, Zakharia Y, Bryce A, Murad M. Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis. Critical Reviews In Oncology/Hematology 2022, 175: 103706. PMID: 35537621, DOI: 10.1016/j.critrevonc.2022.103706.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaAbsolute benefitCell carcinomaTreatment-related grade 3Adjuvant treatment optionsHigher adverse eventsDisease-free survivalRisk-adapted strategyDelays disease progressionLarger tumor sizeEvidence synthesis frameworkAdjuvant therapyAdjuvant treatmentOverall survivalAdverse eventsNodal positivityLeibovich scoreTumor sizeTreatment optionsDisease progressionRisk groupsGrade 3Current evidenceComparative effectivenessSystematic review
2021
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis
Riaz I, Fuentes H, Naqvi S, He H, Sipra Q, Tafur A, Padranos L, Wysokinski W, Marshall A, Vandvik P, Montori V, Bryce A, Liu H, Badgett R, Murad M, McBane R. Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis. Mayo Clinic Proceedings 2021, 97: 308-324. PMID: 34172290, DOI: 10.1016/j.mayocp.2020.10.041.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsCancer-associated thrombosisTreatment of CATMajor bleedingSystematic reviewOral anticoagulantsRecurrent venous thromboembolism (VTE) eventsRelevant nonmajor bleedingUse of apixabanVenous thromboembolism eventsNetwork Meta-AnalysisStandard of careDifferent treatment optionsMixed treatment comparisonNonmajor bleedingThromboembolism eventsVTE recurrenceControlled TrialsWeight heparinTreatment optionsDalteparinHigh riskCurrent evidenceBleedingMeta-Analysis